Tarsus Pharmaceuticals & SpringWorks Therapeutics: Jonathan Faison's top 2 picks
Jonathan Faison runs the ROTY Biotech Community. Why he's high on Tarsus Pharmaceuticals and his #1 holding, SpringWorks Therapeutics (0:30). Data risk for Ogsiveo and Mirdametinib (5:50). This is an excerpt from a recent episode.
Show Notes:
Biotech's Hidden Gems: Smart Strategies For A Challenging Market
SpringWorks Therapeutics Q3 2024 Earnings Call Transcript
Read the transcripts
For full access to analyst ratings, stock quant scores and dividend grades, subscribe to Seeking Alpha Premium at seekingalpha.com/subscriptions
Show Notes:
Biotech's Hidden Gems: Smart Strategies For A Challenging Market
SpringWorks Therapeutics Q3 2024 Earnings Call Transcript
Read the transcripts
For full access to analyst ratings, stock quant scores and dividend grades, subscribe to Seeking Alpha Premium at seekingalpha.com/subscriptions
You May Also Like
Company Interviews
Crux Investor

Mission Matters Business Podcast with Adam Torres
Adam Torres

Marketplace
Marketplace

Marketplace All-in-One
Marketplace

Closing Bell
CNBC

Datasets
Visionary

Stock Movers
iHeartPodcasts

Next Day Prep
WaveRider Markets

One Rental At A Time
Michael Zuber

Jota Jota Podcast
ATrinca Mídia
Community discussion